baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Supernus Pharmaceuticals Inc/ US8684591089 /

03/09/2024 22:00:00	Chg. -0.4500	Volume	Bid00:36:25	Ask00:36:25	High	Low
34.7100USD	-1.28%	380,700 Turnover: 8.46 mill.	33.2300Bid Size: 100	35.7400Ask Size: 100	34.9300	34.3900

GlobeNewswire 28/08 Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

GlobeNewswire 19/08 Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

GlobeNewswire 06/08 Supernus Announces Second Quarter 2024 Financial Results

GlobeNewswire 01/08 Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

GlobeNewswire 23/07 Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call ...

GlobeNewswire 30/05 Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire 23/05 Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...

GlobeNewswire 21/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...

GlobeNewswire 12/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...

GlobeNewswire 09/05 Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...

GlobeNewswire 08/05 Supernus Announces First Quarter 2024 Financial Results

GlobeNewswire 02/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...

GlobeNewswire 01/05 Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

GlobeNewswire 24/04 Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...

GlobeNewswire 24/04 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...

GlobeNewswire 08/04 Supernus Provides Regulatory Update for SPN-830

GlobeNewswire 26/03 MannKind Announces CFO Transition

GlobeNewswire 06/03 Supernus to Participate in Two Upcoming Investor Conferences

GlobeNewswire 28/02 Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire 27/02 Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 13/02 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Co...

GlobeNewswire 05/02 Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

GlobeNewswire 02/02 SAB Biotherapeutics Announces Executive Leadership Change

GlobeNewswire 08/11/2023 Supernus Announces Third Quarter 2023 Financial Results

GlobeNewswire 07/11/2023 Supernus to Participate in the Jefferies London Healthcare Conference

Supernus Pharmaceuticals Inc/ US8684591089 /

If you wish to receive reply to your feedback, please provide your email address.